Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)

MONMOUTH JUNCTION, N.J. - 
      MicroDose 
      Therapeutx Inc. (formerly MicroDose Technologies) tod
Posted : Mon, 09 Nov 2009 19:01:04 GMT
Author : MicroDose Therapeutx Inc.
Category : Press Release
News Alerts by Email ( click here )
Press Release News | Home
MONMOUTH JUNCTION, N.J. - (Business Wire) MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637. This highly potent compound has demonstrated antiviral activity in preclinical studies in both prophylaxis and treatment, and was generally well tolerated in multiple adult volunteer Phase I studies. MicroDose plans to develop the newly acquired compound in dry powder format for inhalation via MicroDose’s novel dry powder inhaler (DPI).

RSV is a highly contagious virus that is a major health threat to several high-risk populations and, with no effective treatments presently available, represents a major unmet medical need. RSV infects over 90% of children worldwide during the first two years of life and causes considerable morbidity and mortality in premature infants, the immuno-compromised, the elderly, and individuals with asthma and chronic obstructive pulmonary disease (COPD).

Commenting on the acquisition, Anand Gumaste, President & CEO of MicroDose said, “Earlier this year we announced that we would be expanding our mission by developing proprietary products that address large market opportunities and are enabled by our game-changing drug delivery technologies. The acquisition of ViroPharma’s portfolio is a perfect fit with this strategy, as it leverages our next generation inhaler platform as well as our experience in respiratory product development to address a large unmet need in RSV disease.”

“The unique capabilities of the MicroDose inhaler are ideal for the delivery of MDT-637 as it can realize the molecule’s broadest potential across the range of populations from pediatric to the elderly, groups not well served by today’s DPIs. The potential for both treatment and prevention across this spectrum of patients, combined with non-invasive inhaled delivery to the site of infection, could greatly expand this market,” explains Scott Fleming, MicroDose’s Sr. Vice President, Sales & Marketing.

About RSV disease

RSV is a pathogen that attacks the human respiratory tract. There are currently no treatment options approved in the U.S. for this virus among the infant, pediatric, and adult populations that are susceptible to it. The February 2009 edition of the New England Journal of Medicine stated that “RSV is associated with substantial morbidity in US children in both the inpatient and outpatient settings and..... its control is a worldwide priority.” Globally, the annual death rate from RSV is estimated at 160,000 and the clinical burden of RSV infection is comparable to that of influenza. The market opportunity for treatments addressing RSV is significant and growing. MedImmune’s monoclonal antibody, Synagis®, an intramuscular injection approved only for prophylactic use against RSV in premature infants, has annual worldwide sales in excess of $1 billion.

About MDT-637

MDT-637 is a clinical stage product that has been shown to effectively block RSV infection both in vitro and in the cotton rat, which is the accepted animal model for RSV infection. MDT-637 acts by targeting the viral fusion protein, which is the only validated target for RSV treatments. The compound is inhaled, which allows for rapid delivery to the site of virus infection, the lungs, and has been shown to be safe and well tolerated in multiple human safety trials. Results from animal studies indicate that MDT-637 could find use as both a preventative and a treatment of RSV infection. MDT-637 will be formulated for pulmonary delivery via MicroDose’s proprietary dry powder inhaler.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications. The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies. MicroDose’s products and platforms currently target respiratory disease states such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV), as well as diabetes, hypertension, and hyperlipidemia. More can be found at our website; www.mdtx.com.

MicroDose Therapeutx Inc.
Scott Fleming, 732-355-2114
Senior V.P., Sales & Marketing
sfleming@mdtx.com
or
Ex Machina D x M
Judith Fleischer, 908-469-0554
jfleischer@exmachinadxm.com


Copyright © 2008 Business Wire. All rights reserved.
Share/Save/Bookmark

Article : MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News

Research and Markets: Wine - Scandinavia Industry Guide
DUBLIN - Research and Markets (

Toshiba Of Canada Limited & Esnatech Enables SIP Based Collaboration for SMB Customers
Toshiba of Canada Limited releases new SIP based Meet-Me conference server for the Toshiba Strata CIX IP Communications platform/I/P PRichmond Hill, Ont., Canada (PRWEB) November 25, 2009 -- Toshiba of Canada Limited a leader in VoIP based communications & Esnatech, a leader in unif...

BenefitPackages.com Reveals the Truth About No or Low Cost Medicare Supplement Plan Options Including Anthem Blue Cross Freedom Blue Regional PPO
BenefitPackages.com, California's designated Premier Partner for Anthem Blue Cross, is working to raise awareness during the November 15 - December 31 Annual Enrollment Period for seniors that allows them to enroll in a zero-cost PPO Medicare Advantage plan. Freedom Blue PPO plans from Anthem...

Ratedpeople.com Offers Roof Maintenance Tips For Winter
Home Owners Should Be Mindful Of Roofing Conditions/I/P PLondon, UK (PRWEB) November 25, 2009 -- Ratedpeople.com, the UK's largest match making service for home improvers and recommended tradesmen, has offered a series of tips for home owners looking to avoid problems with their roofing...

Green Supply Chain.org Receives 2009 Best of Business Award
Small Business Commerce Association's award honors achievement./I/P PSan Francisco, CA (PRWEB) November 24, 2009 -- Green Supply Chain.org, LLC has been selected for the 2009 Best of Business Award in the Commercial Nonphysical Research category by the Small Business Commerce Associatio...

jc's shops Celebrates First Anniversary, Aims to Provide Incentives for Customers During Tough Times
jc's shops, which recently celebrated its first year of operation, is trying to give its customers good value for quality products during hard economic times./I/P PSwedesboro, N.J. (PRWEB) November 25, 2009 -- a href= http://www.myshopkart.net/jcshops/ onclick= linkClick( this.href );...

Have A World Class Branson Christmas Vacation at Bargain Prices
Enjoy the best Christmas celebration in America with a Branson Vacation. And this year having a Branson Christmas is more affordable than ever thanks to shops and resorts in Branson offering holiday discounts./I/P PBranson, MO (PRWEB) November 25, 2009 -- Branson, Missouri is often call...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.